首页 > 最新文献

Wspolczesna Onkologia-Contemporary Oncology最新文献

英文 中文
Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy. 明确放化疗口咽癌患者PD-L1表达与毒性和反应的相关性。
IF 1.8 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-09-07 DOI: 10.5114/wo.2022.118227
Smriti Srivastava, Madhup Rastogi, Ajeet Kumar Gandhi, Rohini Khurana, Rahat Hadi, Shantanu Sapru, Anoop Srivastava, Avinav Bharati, Nuzhat Husain, Surendra Prasad Mishra, Kamal Sahni

Introduction: The programmed death receptor ligand 1 (PD-L1) is a cell-surface glycoprotein expressed in tumour cells (TCs) and is also upregulated in tumour infiltrating lymphocytes. The effect of PD-L1 expression on TCs and tumour-infiltrating lymphocytes (TILs) on acute radiation toxicity and response in oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy is less known.

Material and methods: Squamous cell carcinoma of oropharynx with stage II-IVA (AJCC 8th) were recruited in this prospective observational study. Definitive radiation therapy (RT) of 70 Gray in 35 fractions at 2 Gray per fraction, 5 fractions a week in 2 phases was delivered with concurrent chemotherapy (cisplatin 40 mg/m2 weekly). Patients were assessed weekly for acute toxicities with Radiation Therapy Oncology Group criteria. Response assessment was done at 3 months post RT according to World Health Organization response assessment criteria. The programmed death receptor ligand 1 expression in TCs and TILs was correlated with acute toxicity and survival.

Results: Of 51 patients, 20 (39.2%) had PD-L1 expression in TCs and 18 (35.3%) in TILs. Patients with PD-L1 expression in TCs had fewer grade ≥ 3 oral mucositis (25% vs. 58%; p = 0.02) and grade ≥ 3 dysphagia (25% vs. 55%; p = 0.046). The programmed death receptor ligand 1-tumour infiltrating lymphocytes positives had lower ≥ 3 grade oral mucositis (22% vs. 58%; p = 0.02) and ≥ 3 grade dysphagia (17% vs. 58%; p = 0.007). Two-year overall and progression-free survival rate for the PD-L1-tumour-positive vs. PD-L1-tumour-negative group was not different (p > 0.5).

Conclusions: Positive PD-L1 expression is associated with fewer acute radiation toxicities, and this could be used as a potential biomarker.

程序性死亡受体配体1 (PD-L1)是一种在肿瘤细胞(tc)中表达的细胞表面糖蛋白,在肿瘤浸润淋巴细胞中也表达上调。PD-L1在tc和肿瘤浸润淋巴细胞(til)中的表达对同步放化疗口咽鳞状细胞癌急性放射毒性和反应的影响尚不清楚。材料和方法:本前瞻性观察研究招募了II-IVA期口咽鳞状细胞癌(AJCC 8)。最终放射治疗(RT)为70 Gray,分为35个分数,每个分数2 Gray,每周5个分数,分2期进行,同时进行化疗(顺铂每周40 mg/m2)。每周根据放射治疗肿瘤组标准评估患者的急性毒性。根据世界卫生组织反应评估标准,于放疗后3个月进行反应评估。程序性死亡受体配体1在TCs和TILs中的表达与急性毒性和生存相关。结果:51例患者中,20例(39.2%)tc中有PD-L1表达,18例(35.3%)til中有PD-L1表达。TCs中PD-L1表达的患者较少发生≥3级口腔黏膜炎(25% vs. 58%;P = 0.02)和≥3级吞咽困难(25% vs 55%;P = 0.046)。程序性死亡受体配体1-肿瘤浸润淋巴细胞阳性患者有较低的≥3级口腔黏膜炎(22%对58%;P = 0.02)和≥3级吞咽困难(17% vs. 58%;P = 0.007)。pd - l1肿瘤阳性组与pd - l1肿瘤阴性组的两年总生存率和无进展生存率无差异(p > 0.5)。结论:PD-L1阳性表达与较少的急性放射毒性相关,这可以作为一种潜在的生物标志物。
{"title":"Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy.","authors":"Smriti Srivastava,&nbsp;Madhup Rastogi,&nbsp;Ajeet Kumar Gandhi,&nbsp;Rohini Khurana,&nbsp;Rahat Hadi,&nbsp;Shantanu Sapru,&nbsp;Anoop Srivastava,&nbsp;Avinav Bharati,&nbsp;Nuzhat Husain,&nbsp;Surendra Prasad Mishra,&nbsp;Kamal Sahni","doi":"10.5114/wo.2022.118227","DOIUrl":"https://doi.org/10.5114/wo.2022.118227","url":null,"abstract":"<p><strong>Introduction: </strong>The programmed death receptor ligand 1 (PD-L1) is a cell-surface glycoprotein expressed in tumour cells (TCs) and is also upregulated in tumour infiltrating lymphocytes. The effect of PD-L1 expression on TCs and tumour-infiltrating lymphocytes (TILs) on acute radiation toxicity and response in oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy is less known.</p><p><strong>Material and methods: </strong>Squamous cell carcinoma of oropharynx with stage II-IVA (AJCC 8<sup>th</sup>) were recruited in this prospective observational study. Definitive radiation therapy (RT) of 70 Gray in 35 fractions at 2 Gray per fraction, 5 fractions a week in 2 phases was delivered with concurrent chemotherapy (cisplatin 40 mg/m<sup>2</sup> weekly). Patients were assessed weekly for acute toxicities with Radiation Therapy Oncology Group criteria. Response assessment was done at 3 months post RT according to World Health Organization response assessment criteria. The programmed death receptor ligand 1 expression in TCs and TILs was correlated with acute toxicity and survival.</p><p><strong>Results: </strong>Of 51 patients, 20 (39.2%) had PD-L1 expression in TCs and 18 (35.3%) in TILs. Patients with PD-L1 expression in TCs had fewer grade ≥ 3 oral mucositis (25% vs. 58%; <i>p</i> = 0.02) and grade ≥ 3 dysphagia (25% vs. 55%; <i>p</i> = 0.046). The programmed death receptor ligand 1-tumour infiltrating lymphocytes positives had lower ≥ 3 grade oral mucositis (22% vs. 58%; <i>p</i> = 0.02) and ≥ 3 grade dysphagia (17% vs. 58%; <i>p</i> = 0.007). Two-year overall and progression-free survival rate for the PD-L1-tumour-positive vs. PD-L1-tumour-negative group was not different (<i>p</i> > 0.5).</p><p><strong>Conclusions: </strong>Positive PD-L1 expression is associated with fewer acute radiation toxicities, and this could be used as a potential biomarker.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/51/WO-26-47517.PMC9641626.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40466078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. 多西他赛治疗转移性激素敏感性前列腺癌的疗效以及与血红蛋白、白蛋白、淋巴细胞和血小板评分的相关性。
IF 2.9 Q2 ONCOLOGY Pub Date : 2022-01-01 Epub Date: 2022-10-24 DOI: 10.5114/wo.2022.120592
Heba F Taha, Dalia Hamouda Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed, Mostafa Kamel, Mohamed Elderey, Ola M Elfarargy

Introduction: We aimed to evaluate the outcome of treatment with docetaxel plus androgen deprivation therapy (ADT) in newly diagnosed patients with metastatic high tumor burden hormone-sensitive prostate cancer (mHSPC) and correlated the outcome with hemoglobin, albumin, lymphocyte and platelets (HALP) score.

Material and methods: Six cycles of docetaxel plus ADT were given to 50 patients with high burden mHSPC. Baseline HALP score was calculated and disease outcome was tabulated; moreover, the prognostic impact of the HALP score in response to treatment and survival was calculated.

Results: We found a significant association between high HALP score and response to treatment where a higher rate of complete response occurred in patients with a high HALP score than in patients with a low HALP score (53.8% vs. 5.4% respectively, p-value = 0.001). Patients with ≥ 12-month-duration castration-resistant prostate cancer (CRPC) had a significantly higher HALP score compared to patients with a lower HALP score (84.6% vs. 35.1% respectively, p-value = 0.002); 18-month-duration CRPC-free survival was significantly greater in patients with higher HALP score than patients with a lower HALP score (23.1% and 5.4% respectively, p-value < 0.001). Patients with a high HALP score had insignificantly higher mean overall survival than patients with a low HALP score (mean: 22.91 and 20.66 months respectively, p-value = 0.230).

Conclusions: Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.

简介我们旨在评估多西他赛联合雄激素剥夺疗法(ADT)对新诊断的转移性高肿瘤负荷激素敏感性前列腺癌(mHSPC)患者的治疗效果,并将治疗效果与血红蛋白、白蛋白、淋巴细胞和血小板(HALP)评分相关联:材料: 50 名高负荷 mHSPC 患者接受了 6 个周期的多西他赛加 ADT 治疗。此外,还计算了HALP评分对治疗反应和生存期的预后影响:结果:我们发现 HALP 高分与治疗反应之间存在明显关联,HALP 高分患者的完全反应率高于 HALP 低分患者(分别为 53.8% 对 5.4%,P 值 = 0.001)。病程≥12个月的阉割耐药前列腺癌(CRPC)患者的HALP评分明显高于HALP评分较低的患者(分别为84.6%和35.1%,P值=0.002);HALP评分较高的患者的18个月无CRPC生存率明显高于HALP评分较低的患者(分别为23.1%和5.4%,P值<0.001)。HALP评分高的患者的平均总生存期明显高于HALP评分低的患者(分别为22.91个月和20.66个月,P值=0.230):我们的研究结果证实,多西他赛联合ADT治疗高负担、可耐受的mHSPC患者有一定疗效。我们发现,HALP评分是治疗获益的一个独立预测因素;我们可以将其作为一种简便的方法,对患者进行分层,以便适当选择治疗方法,从而获得更好的耐受性和疗效。
{"title":"Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score.","authors":"Heba F Taha, Dalia Hamouda Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed, Mostafa Kamel, Mohamed Elderey, Ola M Elfarargy","doi":"10.5114/wo.2022.120592","DOIUrl":"10.5114/wo.2022.120592","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to evaluate the outcome of treatment with docetaxel plus androgen deprivation therapy (ADT) in newly diagnosed patients with metastatic high tumor burden hormone-sensitive prostate cancer (mHSPC) and correlated the outcome with hemoglobin, albumin, lymphocyte and platelets (HALP) score.</p><p><strong>Material and methods: </strong>Six cycles of docetaxel plus ADT were given to 50 patients with high burden mHSPC. Baseline HALP score was calculated and disease outcome was tabulated; moreover, the prognostic impact of the HALP score in response to treatment and survival was calculated.</p><p><strong>Results: </strong>We found a significant association between high HALP score and response to treatment where a higher rate of complete response occurred in patients with a high HALP score than in patients with a low HALP score (53.8% vs. 5.4% respectively, <i>p</i>-value = 0.001). Patients with ≥ 12-month-duration castration-resistant prostate cancer (CRPC) had a significantly higher HALP score compared to patients with a lower HALP score (84.6% vs. 35.1% respectively, <i>p</i>-value = 0.002); 18-month-duration CRPC-free survival was significantly greater in patients with higher HALP score than patients with a lower HALP score (23.1% and 5.4% respectively, <i>p</i>-value < 0.001). Patients with a high HALP score had insignificantly higher mean overall survival than patients with a low HALP score (mean: 22.91 and 20.66 months respectively, <i>p</i>-value = 0.230).</p><p><strong>Conclusions: </strong>Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/48/WO-26-48040.PMC9641632.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40466079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver metastasis or a pseudocyst? A rare presentation of leiomyosarcoma's metastasis in the liver. 肝转移还是假性囊肿?肝脏平滑肌肉瘤转移的罕见表现。
IF 1.8 Q3 Medicine Pub Date : 2022-01-01 DOI: 10.5114/wo.2022.124595
Adrian Bednarek, Julia Sołek, Konrad Szymczyk, Mikołaj Gwardys, Agnieszka Wierzchniewska-Ławska, Dorota Jesionek-Kupnicka, Marcin Braun, Hanna M Romańska

Gastrointestinal neoplasms most commonly metastasize to the liver, where they are typically found as solid and hypervascular lesions. Here, we describe a case of a 44-year-old man with a leiomyosarcoma of the rectum, who at the time of diagnosis presented with a small (5 mm in diameter) cyst-like lesion in the liver. Positron emission tomography demonstrated no increased metabolism in the area of the cyst, suggesting a benign character of the lesion. However, after 3 years, CT scans revealed enlargement of the cyst, and local surgical excision was performed. The results of histopathological examination of the resected material were consistent with metastatic leiomyosarcoma. Subsequently, the patient developed lung metastases and died within 2 years. Our case describes a very rare presentation of leiomyosarcoma's metastasis that led to an ill-fated misdiagnosis and dismal disease outcome.

胃肠道肿瘤最常转移到肝脏,通常表现为实性和高血管病变。在这里,我们描述一个44岁的男性直肠平滑肌肉瘤病例,他在诊断时表现为肝脏小(直径5mm)囊肿样病变。正电子发射断层扫描显示囊肿区域未见代谢增加,提示病变为良性。然而,3年后,CT扫描显示囊肿扩大,并进行了局部手术切除。切除的组织病理检查结果与转移性平滑肌肉瘤一致。随后,患者发生肺转移并在2年内死亡。我们的病例描述了一个非常罕见的平滑肌肉瘤转移的表现,导致了不幸的误诊和令人沮丧的疾病结果。
{"title":"Liver metastasis or a pseudocyst? A rare presentation of leiomyosarcoma's metastasis in the liver.","authors":"Adrian Bednarek,&nbsp;Julia Sołek,&nbsp;Konrad Szymczyk,&nbsp;Mikołaj Gwardys,&nbsp;Agnieszka Wierzchniewska-Ławska,&nbsp;Dorota Jesionek-Kupnicka,&nbsp;Marcin Braun,&nbsp;Hanna M Romańska","doi":"10.5114/wo.2022.124595","DOIUrl":"https://doi.org/10.5114/wo.2022.124595","url":null,"abstract":"<p><p>Gastrointestinal neoplasms most commonly metastasize to the liver, where they are typically found as solid and hypervascular lesions. Here, we describe a case of a 44-year-old man with a leiomyosarcoma of the rectum, who at the time of diagnosis presented with a small (5 mm in diameter) cyst-like lesion in the liver. Positron emission tomography demonstrated no increased metabolism in the area of the cyst, suggesting a benign character of the lesion. However, after 3 years, CT scans revealed enlargement of the cyst, and local surgical excision was performed. The results of histopathological examination of the resected material were consistent with metastatic leiomyosarcoma. Subsequently, the patient developed lung metastases and died within 2 years. Our case describes a very rare presentation of leiomyosarcoma's metastasis that led to an ill-fated misdiagnosis and dismal disease outcome.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/bf/WO-26-50024.PMC9933358.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome. 急性淋巴细胞白血病患儿l -天冬酰胺酶治疗的监测,重点关注沉默失活及其对治疗结果的影响
IF 1.8 Q3 Medicine Pub Date : 2022-01-01 DOI: 10.5114/wo.2023.124972
Malgorzata Czogala, Iwona Rogatko, Katarzyna Pawińska-Wąsikowska, Wojciech Czogała, Wioletta Bal, Małgorzata Ciebiera, Radosław Chaber, Agnieszka Chodała-Grzywacz, Grażyna Karolczyk, Krystyna Sztefko, Walentyna Balwierz, Szymon Skoczeń

Introduction: The aim of the study was to analyse the frequency of silent inactivation and allergic reaction to asparaginase (ASP) and its impact on treatment results in patients with lymphoblastic leukaemia.

Material and methods: Seventy patients with acute lymphoblastic leukaemia treated with ASP were enrolled in the study. Asparaginase activity was monitored. The patients were switched to another ASP formulation after allergy or inactivation. The treatment results were analysed.

Results: Silent inactivation of native E. coli ASP was diagnosed in 5 patients (7%) and allergy in 34 patients (49%), and these patients were switched to pegylated ASP (PEG-ASP). Silent inactivation of PEG-ASP occurred in 8 patients (23%) and allergy in 6 patients (17%). Eight children continued therapy with Erwinase, and 4 did not switch to Erwinase after inactivation of PEG-ASP. Allergy to Erwinase occurred in 2 patients (22%); there was no inactivation. No significant differences in outcome were found between the groups of patients with and without allergy or silent inactivation of ASP. Due to regular monitoring and switching to other ASP preparations after allergy or silent inactivation, therapeutic activity was ensured in almost all patients.

Conclusions: Monitoring of ASP activity is crucial to recognize silent inactivation and to guarantee treatment effectiveness by switching to other ASP preparations.

本研究的目的是分析淋巴细胞白血病患者天冬酰胺酶(ASP)沉默性失活和过敏反应的频率及其对治疗结果的影响。材料与方法:采用ASP治疗急性淋巴细胞白血病患者70例。监测天冬酰胺酶活性。患者在过敏或失活后切换到另一种ASP制剂。对处理结果进行了分析。结果:5例(7%)患者被诊断为原生大肠杆菌ASP沉默失活,34例(49%)患者被诊断为过敏,这些患者改用聚乙二醇化ASP (PEG-ASP)。8例(23%)患者发生PEG-ASP沉默失活,6例(17%)患者发生过敏。8名儿童继续使用Erwinase治疗,4名儿童在PEG-ASP失活后未改用Erwinase。2例(22%)发生葡萄蛋白酶过敏;没有失活。结果在有和没有过敏或ASP沉默失活的患者组之间没有发现显著差异。由于定期监测并在过敏或沉默失活后切换到其他ASP制剂,几乎所有患者的治疗活性都得到了保证。结论:监测ASP活性对于识别无症状失活和保证切换到其他ASP制剂的治疗效果至关重要。
{"title":"Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome.","authors":"Malgorzata Czogala,&nbsp;Iwona Rogatko,&nbsp;Katarzyna Pawińska-Wąsikowska,&nbsp;Wojciech Czogała,&nbsp;Wioletta Bal,&nbsp;Małgorzata Ciebiera,&nbsp;Radosław Chaber,&nbsp;Agnieszka Chodała-Grzywacz,&nbsp;Grażyna Karolczyk,&nbsp;Krystyna Sztefko,&nbsp;Walentyna Balwierz,&nbsp;Szymon Skoczeń","doi":"10.5114/wo.2023.124972","DOIUrl":"https://doi.org/10.5114/wo.2023.124972","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to analyse the frequency of silent inactivation and allergic reaction to asparaginase (ASP) and its impact on treatment results in patients with lymphoblastic leukaemia.</p><p><strong>Material and methods: </strong>Seventy patients with acute lymphoblastic leukaemia treated with ASP were enrolled in the study. Asparaginase activity was monitored. The patients were switched to another ASP formulation after allergy or inactivation. The treatment results were analysed.</p><p><strong>Results: </strong>Silent inactivation of native <i>E. coli</i> ASP was diagnosed in 5 patients (7%) and allergy in 34 patients (49%), and these patients were switched to pegylated ASP (PEG-ASP). Silent inactivation of PEG-ASP occurred in 8 patients (23%) and allergy in 6 patients (17%). Eight children continued therapy with Erwinase, and 4 did not switch to Erwinase after inactivation of PEG-ASP. Allergy to Erwinase occurred in 2 patients (22%); there was no inactivation. No significant differences in outcome were found between the groups of patients with and without allergy or silent inactivation of ASP. Due to regular monitoring and switching to other ASP preparations after allergy or silent inactivation, therapeutic activity was ensured in almost all patients.</p><p><strong>Conclusions: </strong>Monitoring of ASP activity is crucial to recognize silent inactivation and to guarantee treatment effectiveness by switching to other ASP preparations.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/6b/WO-26-50127.PMC9933359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10765702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of inflammation biomarkers in differential diagnosis of pelvic tumours of ovarian origin: a single-centre observational study. 炎症生物标志物在卵巢源性盆腔肿瘤鉴别诊断中的作用:一项单中心观察研究。
IF 1.8 Q3 Medicine Pub Date : 2021-01-01 Epub Date: 2021-04-15 DOI: 10.5114/wo.2021.105072
Victoria Psomiadou, Anastasia Prodromidou, Elpis Galati, Ioannis D Kostakis, Athanasios Maliaros, Ioannis Mamais, Nikolaos Blontzos, Fotios Lefkopoulos, Christos Iavazzo, George Vorgias

Aim of the study: Our aim was to analyse the feasibility of white blood cell and platelet counts along with their ratios as a prognostic factor in patients who underwent surgery for ovarian mass.

Material and methods: We retrospectively studied the patients admitted in the Department of Gynaecology due to adnexal mass. The potential association of the neutrophil-to-lymphocyte-ratio (NLR), neutrophil-to-monocyte (NMR), platelet-to-lymphocyte (PLR), lymphocyte-to-monocyte (LMR), monocyte-to-platelet, and malignancy was evaluated.

Results: Patients with malignant tumours were found with significantly higher ratios of NLR (p < 0.001) and PLR (p < 0.001) and lower LMR ratio (p < 0.001) compared to those with benign tumours. Furthermore, higher lymphocyte count (p = 0.04) and platelet count (p = 0.004) were found in cancer patients when compared with borderline tumours. No significant variations were detected regarding white blood cell count (p = 0.238), NMR ratio (p = 0.28), platelet-to-neutrophil ratio (p = 0.12), and platelet-to-monocyte ratio (p = 0.34).

Conclusions: Inflammation biomarker ratios can easily and inexpensive assist in distinguishing malignant ovarian tumours from benign ones.

研究目的:我们的目的是分析白细胞和血小板计数及其比率作为卵巢肿块手术患者预后因素的可行性。材料和方法:我们回顾性研究了因附件肿块入院的妇科患者。评估中性粒细胞与淋巴细胞比率(NLR)、中性粒细胞与单核细胞比率(NMR)、血小板与淋巴细胞比率(PLR)、淋巴细胞与单核细胞比率(LMR)、单核细胞与血小板比率和恶性肿瘤之间的潜在关联。结果:恶性肿瘤患者NLR比(p < 0.001)、PLR比(p < 0.001)显著高于良性肿瘤患者,LMR比(p < 0.001)显著低于良性肿瘤患者。此外,与交界性肿瘤患者相比,肿瘤患者淋巴细胞计数(p = 0.04)和血小板计数(p = 0.004)较高。白细胞计数(p = 0.238)、核磁共振比(p = 0.28)、血小板与中性粒细胞比(p = 0.12)和血小板与单核细胞比(p = 0.34)均未发现显著差异。结论:炎症标志物比值可以方便、廉价地帮助鉴别卵巢恶性肿瘤和良性肿瘤。
{"title":"The role of inflammation biomarkers in differential diagnosis of pelvic tumours of ovarian origin: a single-centre observational study.","authors":"Victoria Psomiadou,&nbsp;Anastasia Prodromidou,&nbsp;Elpis Galati,&nbsp;Ioannis D Kostakis,&nbsp;Athanasios Maliaros,&nbsp;Ioannis Mamais,&nbsp;Nikolaos Blontzos,&nbsp;Fotios Lefkopoulos,&nbsp;Christos Iavazzo,&nbsp;George Vorgias","doi":"10.5114/wo.2021.105072","DOIUrl":"https://doi.org/10.5114/wo.2021.105072","url":null,"abstract":"<p><strong>Aim of the study: </strong>Our aim was to analyse the feasibility of white blood cell and platelet counts along with their ratios as a prognostic factor in patients who underwent surgery for ovarian mass.</p><p><strong>Material and methods: </strong>We retrospectively studied the patients admitted in the Department of Gynaecology due to adnexal mass. The potential association of the neutrophil-to-lymphocyte-ratio (NLR), neutrophil-to-monocyte (NMR), platelet-to-lymphocyte (PLR), lymphocyte-to-monocyte (LMR), monocyte-to-platelet, and malignancy was evaluated.</p><p><strong>Results: </strong>Patients with malignant tumours were found with significantly higher ratios of NLR (<i>p</i> < 0.001) and PLR (<i>p</i> < 0.001) and lower LMR ratio (<i>p</i> < 0.001) compared to those with benign tumours. Furthermore, higher lymphocyte count (<i>p</i> = 0.04) and platelet count (<i>p</i> = 0.004) were found in cancer patients when compared with borderline tumours. No significant variations were detected regarding white blood cell count (<i>p</i> = 0.238), NMR ratio (<i>p</i> = 0.28), platelet-to-neutrophil ratio (<i>p</i> = 0.12), and platelet-to-monocyte ratio (<i>p</i> = 0.34).</p><p><strong>Conclusions: </strong>Inflammation biomarker ratios can easily and inexpensive assist in distinguishing malignant ovarian tumours from benign ones.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/9f/WO-25-43726.PMC8063895.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds - a single-centre experience. 使用定制模具对非黑色素瘤皮肤癌进行高剂量率近距离放射治疗--单中心经验。
IF 1.8 Q3 Medicine Pub Date : 2021-01-01 Epub Date: 2021-03-24 DOI: 10.5114/wo.2021.104688
Concetta Laliscia, Taiusha Fuentes, Natalina Coccia, Roberto Mattioni, Franco Perrone, Fabiola Paiar

Aim of the study: The aim of this retrospective study was to analyse tumour control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) treated with 192 Ir high-dose-rate (HDR)-brachytherapy (BT) at the Division of Radiotherapy, University of Pisa.

Material and methods: From January 2014 to December 2019 we treated 37 patients (median age 79 years; range 31-91 years) affected by NMSC, with the following histological subtypes: 62.2% basal cell carcinoma and 37.8% squamous cell carcinoma. We analysed 40 lesions with a depth ≤ 5 mm, located in 40.0% scalp, 17.5% nose, 25.0% face, and 17.5% ear, all treated with 192 Ir-based HDR-BT, using tailored custom moulds, with a median of 5 catheters (range, 1-9) spaced 1 cm apart. The most common fractionation scheme was 40 Gy in 8 daily fractions; the biological effective dose was 60 Gy.

Results: The median follow-up was 25 months (range, 3-70 months). The 2-year local control rate was 90%. Common terminology criteria for adverse event (CTCAE vs. 5.0) G1 toxicities were dermatitis (52%), pain (25%), and ulceration (22%). The only G2 acute toxicities were dermatitis and ulceration. The most common G1 late toxicities were fibrosis (17%), atrophy (15%), and hypopigmentation (12%). No G3 or higher acute or late toxicity was reported. Excellent cosmetic results were observed in 65.0% of the lesions; only 1 case (2.5%) reported a poor cosmetic result.

Conclusions: Surface mould HDR-BT is a safe, effective, and well tolerated treatment modality for NMSC and can be considered a good alternative, especially for elderly patients who are often unfit for surgery.

研究目的本回顾性研究旨在分析比萨大学放疗科采用192 Ir高剂量率(HDR)近距离放射治疗(BT)的非黑色素瘤皮肤癌(NMSC)患者的肿瘤控制、毒性和美学效果:2014年1月至2019年12月,我们共治疗了37名NMSC患者(中位年龄79岁,31-91岁不等),其组织学亚型如下62.2%为基底细胞癌,37.8%为鳞状细胞癌。我们分析了深度小于 5 毫米的 40 个病灶,其中 40.0% 位于头皮,17.5% 位于鼻子,25.0% 位于脸部,17.5% 位于耳部,所有病灶均采用 192 铱基 HDR-BT 治疗,使用定制的模具,导管中位数为 5 根(1-9 根不等),间距为 1 厘米。最常见的分型方案是每天 8 次,每次 40 Gy;生物有效剂量为 60 Gy:中位随访时间为 25 个月(3-70 个月)。2年的局部控制率为90%。不良事件通用术语标准(CTCAE vs. 5.0)G1毒性反应为皮炎(52%)、疼痛(25%)和溃疡(22%)。唯一的 G2 急性毒性是皮炎和溃疡。最常见的 G1 后期毒性是纤维化(17%)、萎缩(15%)和色素沉着(12%)。没有 G3 或更高急性或晚期毒性的报告。65.0%的病变具有良好的美容效果,只有1例(2.5%)报告美容效果不佳:表面模塑 HDR-BT 是治疗 NMSC 的一种安全、有效且耐受性良好的治疗方式,可视为一种很好的替代方法,尤其是对于通常不适合手术的老年患者。
{"title":"High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds - a single-centre experience.","authors":"Concetta Laliscia, Taiusha Fuentes, Natalina Coccia, Roberto Mattioni, Franco Perrone, Fabiola Paiar","doi":"10.5114/wo.2021.104688","DOIUrl":"10.5114/wo.2021.104688","url":null,"abstract":"<p><strong>Aim of the study: </strong>The aim of this retrospective study was to analyse tumour control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) treated with 192 Ir high-dose-rate (HDR)-brachytherapy (BT) at the Division of Radiotherapy, University of Pisa.</p><p><strong>Material and methods: </strong>From January 2014 to December 2019 we treated 37 patients (median age 79 years; range 31-91 years) affected by NMSC, with the following histological subtypes: 62.2% basal cell carcinoma and 37.8% squamous cell carcinoma. We analysed 40 lesions with a depth ≤ 5 mm, located in 40.0% scalp, 17.5% nose, 25.0% face, and 17.5% ear, all treated with 192 Ir-based HDR-BT, using tailored custom moulds, with a median of 5 catheters (range, 1-9) spaced 1 cm apart. The most common fractionation scheme was 40 Gy in 8 daily fractions; the biological effective dose was 60 Gy.</p><p><strong>Results: </strong>The median follow-up was 25 months (range, 3-70 months). The 2-year local control rate was 90%. Common terminology criteria for adverse event (CTCAE vs. 5.0) G1 toxicities were dermatitis (52%), pain (25%), and ulceration (22%). The only G2 acute toxicities were dermatitis and ulceration. The most common G1 late toxicities were fibrosis (17%), atrophy (15%), and hypopigmentation (12%). No G3 or higher acute or late toxicity was reported. Excellent cosmetic results were observed in 65.0% of the lesions; only 1 case (2.5%) reported a poor cosmetic result.</p><p><strong>Conclusions: </strong>Surface mould HDR-BT is a safe, effective, and well tolerated treatment modality for NMSC and can be considered a good alternative, especially for elderly patients who are often unfit for surgery.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/90/WO-25-43572.PMC8063903.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contrast-enhanced spectral mammography without and with a delayed image for diagnosing malignancy among mass lesions in dense breast. 不带或带延迟图像的对比增强乳腺造影诊断致密乳腺肿块病变中的恶性肿瘤。
IF 1.8 Q3 Medicine Pub Date : 2021-01-01 Epub Date: 2021-04-06 DOI: 10.5114/wo.2021.105030
Akmaral Serikovna Ainakulova, Zhamilya Zholdybay Zholdybay, Dilyara Radikovna Kaidarova, Natalya Igorevna Inozemtceva, Madina Orazaykyzy Gabdullina, Zhanar Kabdualievna Zhakenova, Alexandra Sergeevna Panina, Dias Kairatovich Toleshbayev, Jandos Mukhtarovich Amankulov

Aim of the study: To analyse the diagnostic performance of contrast-enhanced spectral mammography (CESM) based on morphologic and enhancement patterns of mass lesions in dense breast using different protocols: CESM without delayed image and CESM with delayed image.

Material and methods: A total of 151 informed women with suspicious for malignancy mass lesions in dense breast were included in this study. All of them underwent CESM using 2 protocols. A total of 155 lesions were pathomorphologically verified. We analysed morphologic patterns on low-energy (LE) images and recombined images (RI) by defining the shape, margin, and dynamic patterns based on delayed images.

Results: The comparative analysis revealed that the shape and margins on RI were more significant than those on LE images. The dynamic indicators of CESM were found to be highly significant in dense breasts. The correlation between kinetic curve and histological results demonstrated that a persistent type of curve was common for benign lesions, accounting for 15/22 (68.1%); plateau and washout - for malignant lesions, accounting for 24/89 (26.9%) and 61/89 (68.5%), respectively. Delayed image leads to an increase of specificity up to 12.4%, which is statistically significant. The area under the curve (AUC) in CESM with delayed image is larger than that in CESM without delayed image (p < 0.01).

Conclusions: CESM is sensitive for the differential diagnosis of breast lesions. CESM with delayed image has higher specificity than CESM without delayed image. Delayed images with plateau and washout are typical for malignancy.

本研究的目的:分析对比增强光谱乳房造影(CESM)对致密乳腺肿块病变的形态学和增强模式的诊断性能,采用不同的方案:无延迟图像的CESM和有延迟图像的CESM。材料和方法:本研究共纳入151例可疑乳腺恶性肿块的知情妇女。所有患者均采用2种方案进行CESM。155个病变经病理形态学证实。通过定义形状、边缘和基于延迟图像的动态模式,我们分析了低能图像(LE)和重组图像(RI)的形态模式。结果:对比分析显示,RI图像的形状和边缘比LE图像更明显。CESM的动态指标在致密乳腺中具有显著性。动力学曲线与组织学结果的相关性表明,良性病变常见持续性曲线,占15/22 (68.1%);平台期和洗脱期-恶性病变,分别占24/89(26.9%)和61/89(68.5%)。延迟图像导致特异性提高高达12.4%,具有统计学意义。延迟影像CESM的曲线下面积(AUC)大于未延迟影像CESM (p < 0.01)。结论:CESM对乳腺病变的鉴别诊断具有较高的敏感性。延迟图像的CESM比未延迟图像的CESM具有更高的特异性。伴有平台期和冲洗的延迟图像是恶性肿瘤的典型特征。
{"title":"Contrast-enhanced spectral mammography without and with a delayed image for diagnosing malignancy among mass lesions in dense breast.","authors":"Akmaral Serikovna Ainakulova,&nbsp;Zhamilya Zholdybay Zholdybay,&nbsp;Dilyara Radikovna Kaidarova,&nbsp;Natalya Igorevna Inozemtceva,&nbsp;Madina Orazaykyzy Gabdullina,&nbsp;Zhanar Kabdualievna Zhakenova,&nbsp;Alexandra Sergeevna Panina,&nbsp;Dias Kairatovich Toleshbayev,&nbsp;Jandos Mukhtarovich Amankulov","doi":"10.5114/wo.2021.105030","DOIUrl":"https://doi.org/10.5114/wo.2021.105030","url":null,"abstract":"<p><strong>Aim of the study: </strong>To analyse the diagnostic performance of contrast-enhanced spectral mammography (CESM) based on morphologic and enhancement patterns of mass lesions in dense breast using different protocols: CESM without delayed image and CESM with delayed image.</p><p><strong>Material and methods: </strong>A total of 151 informed women with suspicious for malignancy mass lesions in dense breast were included in this study. All of them underwent CESM using 2 protocols. A total of 155 lesions were pathomorphologically verified. We analysed morphologic patterns on low-energy (LE) images and recombined images (RI) by defining the shape, margin, and dynamic patterns based on delayed images.</p><p><strong>Results: </strong>The comparative analysis revealed that the shape and margins on RI were more significant than those on LE images. The dynamic indicators of CESM were found to be highly significant in dense breasts. The correlation between kinetic curve and histological results demonstrated that a persistent type of curve was common for benign lesions, accounting for 15/22 (68.1%); plateau and washout - for malignant lesions, accounting for 24/89 (26.9%) and 61/89 (68.5%), respectively. Delayed image leads to an increase of specificity up to 12.4%, which is statistically significant. The area under the curve (AUC) in CESM with delayed image is larger than that in CESM without delayed image (<i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>CESM is sensitive for the differential diagnosis of breast lesions. CESM with delayed image has higher specificity than CESM without delayed image. Delayed images with plateau and washout are typical for malignancy.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/30/WO-25-43719.PMC8063896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Epidemiology of lung cancer. 肺癌流行病学。
IF 1.8 Q3 Medicine Pub Date : 2021-01-01 Epub Date: 2021-02-23 DOI: 10.5114/wo.2021.103829
Krishna Chaitanya Thandra, Adam Barsouk, Kalyan Saginala, John Sukumar Aluru, Alexander Barsouk

Lung cancer is the leading cause of global cancer incidence and mortality, accounting for an estimated 2 million diagnoses and 1.8 million deaths. Neoplasms of the lungs are the second most common cancer diagnosis in men and women (after prostate and breast cancer, respectively). With increasing access to tobacco and industrialization in developing nations, lung cancer incidence is rising globally. The average age of diagnosis is 70 years old. Men are twice as likely to be diagnosed with lung cancer, which largely reflects differences in tobacco consumption, although women may be more susceptible due to higher proportions of epidermal growth factor receptor mutations and the effects of oestrogen. African American men in the US are at the highest risk of lung cancer. Family history increases risk by 1.7-fold, with a greater risk among first-degree relatives. Tobacco smoking is the greatest preventable cause of death worldwide, accounting for up to 90% of lung cancer cases, and continued consumption is projected to increase global cancer incidence, particularly in developing nations such as China, Russia, and India. Second-hand smoke among children and spouses has likewise been implicated. Radon from natural underground uranium decay is the second leading cause of lung cancer in the developed world. Occupational hazards such as asbestos and environmental exposures such as air pollution, arsenic, and HIV and Tb infection have all been implicated in lung carcinogenesis, while cannabis smoking, electronic cigarettes, heated tobacco products, and COVID-19 have been hypothesized to increase risk.

肺癌是全球癌症发病率和死亡率的主要原因,估计有200万例诊断和180万例死亡。肺部肿瘤是男性和女性中第二常见的癌症诊断(分别排在前列腺癌和乳腺癌之后)。随着发展中国家越来越多地获得烟草和工业化,全球肺癌发病率正在上升。平均诊断年龄为70岁。男性被诊断为肺癌的可能性是男性的两倍,这在很大程度上反映了烟草消费的差异,尽管由于表皮生长因子受体突变比例较高和雌激素的影响,女性可能更容易受到影响。在美国,非裔美国男性患肺癌的风险最高。家族史使患病风险增加1.7倍,一级亲属患病风险更大。吸烟是世界上最大的可预防死亡原因,占肺癌病例的90%,预计持续消费将增加全球癌症发病率,特别是在中国、俄罗斯和印度等发展中国家。孩子和配偶之间的二手烟也有牵连。天然地下铀衰变产生的氡是发达国家肺癌的第二大原因。石棉等职业危害以及空气污染、砷、艾滋病毒和结核病感染等环境暴露都与肺癌有关,而吸食大麻、电子烟、加热烟草制品和COVID-19被认为会增加风险。
{"title":"Epidemiology of lung cancer.","authors":"Krishna Chaitanya Thandra,&nbsp;Adam Barsouk,&nbsp;Kalyan Saginala,&nbsp;John Sukumar Aluru,&nbsp;Alexander Barsouk","doi":"10.5114/wo.2021.103829","DOIUrl":"https://doi.org/10.5114/wo.2021.103829","url":null,"abstract":"<p><p>Lung cancer is the leading cause of global cancer incidence and mortality, accounting for an estimated 2 million diagnoses and 1.8 million deaths. Neoplasms of the lungs are the second most common cancer diagnosis in men and women (after prostate and breast cancer, respectively). With increasing access to tobacco and industrialization in developing nations, lung cancer incidence is rising globally. The average age of diagnosis is 70 years old. Men are twice as likely to be diagnosed with lung cancer, which largely reflects differences in tobacco consumption, although women may be more susceptible due to higher proportions of epidermal growth factor receptor mutations and the effects of oestrogen. African American men in the US are at the highest risk of lung cancer. Family history increases risk by 1.7-fold, with a greater risk among first-degree relatives. Tobacco smoking is the greatest preventable cause of death worldwide, accounting for up to 90% of lung cancer cases, and continued consumption is projected to increase global cancer incidence, particularly in developing nations such as China, Russia, and India. Second-hand smoke among children and spouses has likewise been implicated. Radon from natural underground uranium decay is the second leading cause of lung cancer in the developed world. Occupational hazards such as asbestos and environmental exposures such as air pollution, arsenic, and HIV and Tb infection have all been implicated in lung carcinogenesis, while cannabis smoking, electronic cigarettes, heated tobacco products, and COVID-19 have been hypothesized to increase risk.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/96/WO-25-43345.PMC8063897.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 70
The complexity of tumour angiogenesis based on recently described molecules. 肿瘤血管生成的复杂性基于最近描述的分子。
IF 1.8 Q3 Medicine Pub Date : 2021-01-01 Epub Date: 2021-04-15 DOI: 10.5114/wo.2021.105075
Weronika Wiśniewska, Michał Kopka, Karolina Siemiątkowska, Marta Magdalena Fudalej, Aleksandra Sobiborowicz, Anna Maria Badowska-Kozakiewicz

Tumour angiogenesis is a crucial factor associated with tumour growth, progression, and metastasis. The whole process is the result of an interaction between a wide range of different molecules, influencing each other. Herein we summarize novel discoveries related to the less known angiogenic molecules such as galectins, pentraxin-3, Ral-interacting protein of 76 kDa (RLIP76), long non-coding RNAs (lncRNAs), B7-H3, and delta-like ligand-4 (DLL-4) and their role in the process of tumour angiogenesis. These molecules influence the most important molecular pathways involved in the formation of blood vessels in cancer, including the vascular endothelial growth factor (VEGF)-vascular endothelial growth factor receptor interaction (VEGFR), HIF1-a activation, or PI3K/Akt/mTOR and JAK-STAT signalling pathways. Increased expression of galectins, RLIP76, and B7H3 has been proven in several malignancies. Pentraxin-3, which appears to inhibit tumour angiogenesis, shows reduced expression in tumour tissues. Anti-angiogenic treatment based mainly on VEGF inhibition has proved to be of limited effectiveness, leading to the development of drug resistance. The newly discovered molecules are of great interest as a potential source of new anti-cancer therapies. Their role as targets for new drugs and as prognostic markers in neoplasms is discussed in this review.

肿瘤血管生成是肿瘤生长、进展和转移的关键因素。整个过程是各种不同分子相互作用、相互影响的结果。在此,我们总结了一些鲜为人知的血管生成分子的新发现,如凝集素、苯甲素-3、76 kDa的RLIP76蛋白、长链非编码rna (lncRNAs)、B7-H3和δ样配体-4 (DLL-4),以及它们在肿瘤血管生成过程中的作用。这些分子影响肿瘤血管形成过程中最重要的分子通路,包括血管内皮生长因子(VEGF)-血管内皮生长因子受体相互作用(VEGFR)、HIF1-a激活或PI3K/Akt/mTOR和JAK-STAT信号通路。凝集素、RLIP76和B7H3的表达增加已在几种恶性肿瘤中得到证实。似乎抑制肿瘤血管生成的pentaxin -3在肿瘤组织中的表达降低。主要基于VEGF抑制的抗血管生成治疗已被证明有效性有限,导致耐药性的发展。这些新发现的分子作为一种新的抗癌疗法的潜在来源而引起了人们的极大兴趣。本文讨论了它们作为新药靶点和肿瘤预后标志物的作用。
{"title":"The complexity of tumour angiogenesis based on recently described molecules.","authors":"Weronika Wiśniewska,&nbsp;Michał Kopka,&nbsp;Karolina Siemiątkowska,&nbsp;Marta Magdalena Fudalej,&nbsp;Aleksandra Sobiborowicz,&nbsp;Anna Maria Badowska-Kozakiewicz","doi":"10.5114/wo.2021.105075","DOIUrl":"https://doi.org/10.5114/wo.2021.105075","url":null,"abstract":"<p><p>Tumour angiogenesis is a crucial factor associated with tumour growth, progression, and metastasis. The whole process is the result of an interaction between a wide range of different molecules, influencing each other. Herein we summarize novel discoveries related to the less known angiogenic molecules such as galectins, pentraxin-3, Ral-interacting protein of 76 kDa (RLIP76), long non-coding RNAs (lncRNAs), B7-H3, and delta-like ligand-4 (DLL-4) and their role in the process of tumour angiogenesis. These molecules influence the most important molecular pathways involved in the formation of blood vessels in cancer, including the vascular endothelial growth factor (VEGF)-vascular endothelial growth factor receptor interaction (VEGFR), HIF1-a activation, or PI3K/Akt/mTOR and JAK-STAT signalling pathways. Increased expression of galectins, RLIP76, and B7H3 has been proven in several malignancies. Pentraxin-3, which appears to inhibit tumour angiogenesis, shows reduced expression in tumour tissues. Anti-angiogenic treatment based mainly on VEGF inhibition has proved to be of limited effectiveness, leading to the development of drug resistance. The newly discovered molecules are of great interest as a potential source of new anti-cancer therapies. Their role as targets for new drugs and as prognostic markers in neoplasms is discussed in this review.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/80/WO-25-43728.PMC8063899.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients. 脂多糖结合蛋白作为结直肠癌患者术后感染和炎症并发症发生的危险因素
IF 1.8 Q3 Medicine Pub Date : 2021-01-01 Epub Date: 2021-10-14 DOI: 10.5114/wo.2021.110051
Yermek Turgunov, Alina Ogizbayeva, Lyudmila Akhmaltdinova, Kayrat Shakeyev

Aim of the study: In this pilot study lipopolysaccharide-binding protein (LBP) levels were assessed as a possible risk factor for development of systemic inflammatory response syndrome (SIRS) and infectious and inflammatory complications in colorectal cancer (CRC) patients after surgery.

Material and methods: For LBP determination venous blood was taken 1 hour before the surgery and 72 hours after it. All patients were stratified by the presence or absence of acute bowel obstruction (ABO), SIRS and complications.

Results: 36 patients with CRC participated in the study. The LBP level before surgery was 879.8 ± 221.8 ng/ml (interquartile range (IQR) 749.3-1028.8); on the 3rd day it was 766.5 ± 159.4 ng/ml (IQR 669.5-847.6), which was a statistically significant decrease (p = 0.004). A decrease in LBP level by more than 280 ng/ml increases the probability of SIRS and complications in operated CRC patients (OR 6.6, 95% CI: 1.1-40.9 and OR 12.0, 95% CI: 1.8-80.4, respectively). In patients with ABO in the presence of SIRS, the LBP value decreased more than in those without SIRS (p = 0.046).

Conclusions: This study demonstrated that the LBP level in the operated CRC patients tends to decrease on the 3rd day after surgery. A bigger decrease in LBP level increases the probability of SIRS and postoperative infectious and inflammatory complications. Therefore, further studies with larger numbers of patients are required.

研究目的:在这项试点研究中,脂多糖结合蛋白(LBP)水平被评估为结直肠癌(CRC)术后发生全身炎症反应综合征(SIRS)以及感染和炎症并发症的可能危险因素。材料与方法:术前1 h、术后72 h分别取静脉血测定腰压。所有患者根据是否存在急性肠梗阻(ABO)、SIRS和并发症进行分层。结果:36例结直肠癌患者参与研究。术前LBP水平879.8±221.8 ng/ml(四分位数间距(IQR) 749.3 ~ 1028.8);第3天为766.5±159.4 ng/ml (IQR 669.5 ~ 847.6),差异有统计学意义(p = 0.004)。LBP水平下降超过280 ng/ml会增加手术结直肠癌患者SIRS和并发症的可能性(OR分别为6.6,95% CI: 1.1-40.9和OR为12.0,95% CI: 1.8-80.4)。有SIRS的ABO患者LBP值下降幅度大于无SIRS的患者(p = 0.046)。结论:本研究表明,结直肠癌术后患者LBP水平在术后第3天呈下降趋势。LBP水平下降幅度越大,发生SIRS和术后感染及炎症并发症的可能性就越大。因此,需要更多患者的进一步研究。
{"title":"Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients.","authors":"Yermek Turgunov,&nbsp;Alina Ogizbayeva,&nbsp;Lyudmila Akhmaltdinova,&nbsp;Kayrat Shakeyev","doi":"10.5114/wo.2021.110051","DOIUrl":"https://doi.org/10.5114/wo.2021.110051","url":null,"abstract":"<p><strong>Aim of the study: </strong>In this pilot study lipopolysaccharide-binding protein (LBP) levels were assessed as a possible risk factor for development of systemic inflammatory response syndrome (SIRS) and infectious and inflammatory complications in colorectal cancer (CRC) patients after surgery.</p><p><strong>Material and methods: </strong>For LBP determination venous blood was taken 1 hour before the surgery and 72 hours after it. All patients were stratified by the presence or absence of acute bowel obstruction (ABO), SIRS and complications.</p><p><strong>Results: </strong>36 patients with CRC participated in the study. The LBP level before surgery was 879.8 ± 221.8 ng/ml (interquartile range (IQR) 749.3-1028.8); on the 3<sup>rd</sup> day it was 766.5 ± 159.4 ng/ml (IQR 669.5-847.6), which was a statistically significant decrease (<i>p</i> = 0.004). A decrease in LBP level by more than 280 ng/ml increases the probability of SIRS and complications in operated CRC patients (OR 6.6, 95% CI: 1.1-40.9 and OR 12.0, 95% CI: 1.8-80.4, respectively). In patients with ABO in the presence of SIRS, the LBP value decreased more than in those without SIRS (<i>p</i> = 0.046).</p><p><strong>Conclusions: </strong>This study demonstrated that the LBP level in the operated CRC patients tends to decrease on the 3<sup>rd</sup> day after surgery. A bigger decrease in LBP level increases the probability of SIRS and postoperative infectious and inflammatory complications. Therefore, further studies with larger numbers of patients are required.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/90/WO-25-45449.PMC8547177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Wspolczesna Onkologia-Contemporary Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1